Alkermes Plc (ALKS) Given Buy Rating at Credit Suisse Group AG

Credit Suisse Group AG reissued their buy rating on shares of Alkermes Plc (NASDAQ:ALKS) in a research note published on Wednesday. Credit Suisse Group AG currently has a $70.00 price target on the stock.

Other research analysts also recently issued reports about the stock. ValuEngine raised shares of Alkermes Plc from a sell rating to a hold rating in a research report on Friday, June 2nd. Morgan Stanley reissued an equal weight rating and set a $62.00 target price on shares of Alkermes Plc in a research report on Monday, April 24th. Jefferies Group LLC reissued a buy rating and set a $70.00 target price on shares of Alkermes Plc in a research report on Monday, April 3rd. Cantor Fitzgerald reaffirmed a neutral rating and issued a $51.00 price objective on shares of Alkermes Plc in a report on Thursday, March 16th. Finally, JPMorgan Chase & Co. set a $78.00 price objective on shares of Alkermes Plc and gave the stock a buy rating in a report on Thursday, April 27th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $64.00.

Shares of Alkermes Plc (NASDAQ ALKS) traded up 1.24% during trading on Wednesday, hitting $60.31. The stock had a trading volume of 717,097 shares. Alkermes Plc has a 1-year low of $39.65 and a 1-year high of $62.50. The company’s market capitalization is $9.24 billion. The firm has a 50-day moving average of $58.04 and a 200 day moving average of $57.11.

Alkermes Plc (NASDAQ:ALKS) last released its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes Plc had a negative net margin of 36.92% and a negative return on equity of 12.75%. The company had revenue of $191.80 million for the quarter, compared to the consensus estimate of $195.79 million. During the same period in the prior year, the company earned ($0.16) earnings per share. The firm’s revenue was up 22.3% on a year-over-year basis. Equities research analysts predict that Alkermes Plc will post ($0.04) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://sleekmoney.com/alkermes-plc-alks-given-buy-rating-at-credit-suisse-group-ag/1892856.html.

In other Alkermes Plc news, CMO Elliot Ehrich sold 11,000 shares of Alkermes Plc stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $56.74, for a total value of $624,140.00. Following the completion of the transaction, the chief marketing officer now directly owns 66,071 shares of the company’s stock, valued at $3,748,868.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard F. Pops sold 50,000 shares of Alkermes Plc stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total transaction of $2,909,500.00. Following the completion of the transaction, the director now directly owns 680,406 shares of the company’s stock, valued at $39,592,825.14. The disclosure for this sale can be found here. Insiders have sold a total of 175,800 shares of company stock worth $10,157,246 in the last ninety days. Insiders own 4.75% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Greenwood Capital Associates LLC bought a new position in Alkermes Plc during the fourth quarter valued at $202,000. Mn Services Vermogensbeheer B.V. raised its stake in shares of Alkermes Plc by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares during the period. Achmea Investment Management B.V. acquired a new stake in shares of Alkermes Plc during the first quarter valued at about $247,000. Nomura Holdings Inc. acquired a new stake in shares of Alkermes Plc during the first quarter valued at about $266,000. Finally, Decatur Capital Management Inc. acquired a new stake in shares of Alkermes Plc during the first quarter valued at about $267,000. 95.52% of the stock is owned by institutional investors and hedge funds.

Alkermes Plc Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/alkermes-plc-alks-given-buy-rating-at-credit-suisse-group-ag/1892856.html

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *